{
    "eid": "2-s2.0-84945934872",
    "title": "A Simple Novel Technique to Estimate Tacrolimus Dosages during the Early Post Kidney Transplantation Period",
    "cover-date": "2015-10-01",
    "subject-areas": [
        {
            "$": "Transplantation",
            "@code": "2747"
        },
        {
            "$": "Surgery",
            "@code": "2746"
        }
    ],
    "keywords": [],
    "authors": [
        "Natavudh Townamchai"
    ],
    "citedby-count": 5,
    "ref-count": 20,
    "ref-list": [
        "Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation",
        "In vivo CYP3A4 activity, CYP3A5 genotype, and hematocrit predict tacrolimus dose requirements and clearance in renal transplant patients",
        "Genetic polymorphisms of the C\u03a5P3A4, C\u03a5P3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus",
        "Novel polymorphisms associated with tacrolimus trough concentrations: Results from a multicenter kidney transplant consortium",
        "Impact of cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients",
        "A pharmacogenetic strategy for immunosuppression based on the CYP3A5 genotype",
        "Optimization of initial tacrolimus dose using pharmacogenetic testing",
        "Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients",
        "Lower tacrolimus daily dose requirements and acute rejection rates in the CYP3A5 nonexpressers than expressers",
        "Pharmacogenomics of drug-metabolizing enzymes: A recent update on clinical implications and endogenous effects",
        "Practical recommendations for pharmacogenomics-based prescription: 2010 ESF-UB Conference on Pharmacogenetics and Pharmacogenomics",
        "Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part i",
        "Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II",
        "The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation",
        "Tacrolimus dose requirements and CYP3A5 genotype and the development of calcineurin inhibitor-associated nephrotoxicity in renal allograft recipients",
        "Effect of CYP3A5 Genotype on Renal Allograft Recipients Treated With Tacrolimus",
        "Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients",
        "CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients",
        "Donor age and renal P-glycoprotein expression associate with chronic histological damage in renal allografts",
        "Dosing tacrolimus based on CYP3A5 genotype: Will it improve clinical outcome?"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "affilname": "Chulalongkorn University",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Baltimore",
            "affilname": "Johns Hopkins Bloomberg School of Public Health",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Bangkok",
            "affilname": "Faculty of Medicine, Chulalongkorn University",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "National Science and Technology Development Agency"
    ]
}